In Utero Haematopoietic Stem Cell Transplantation (Iuhsct)

Renda, Maria Concetta; Maggio, Aurelio

doi:10.4084/mjhid.2009.031

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More vigorous study and research are needed before gene therapy can be used ( 70 ). The success of in-utero hematopoietic stem-cell transplantation will probably serve as the first step toward the management of congenital hematological, metabolic, and immunological diseases ( 71 ). Until now, neither prenatal gene therapy nor stem cell therapy had been tested in DS.…”

Section: Commentmentioning

confidence: 99%

Prenatal and Postnatal Therapies for Down's Syndrome and Associated Developmental Anomalies and Degenerative Deficits: A Systematic Review of Guidelines and Trials

Hasina

Wang²

2022

Front. Med.

View full text Add to dashboard Cite

Down's syndrome (DS) is the most common genetic disorder at birth. Multiple developmental abnormalities before birth and early onset of degenerative deficits after birth are features of DS. Early treatment for the manifestations associated with DS in either prenatal or postnatal period may improve clinical outcomes. However, information available from professional bodies and to communities is very limited. We carried out a systematic review and attempted meta-analysis of clinical trials for developmental abnormalities and degenerative deficits in DS. Only 15 randomized controlled trials (RCTs) in 995 (24 days to 65 years old) individuals with DS showed some improvement in cognitive disorders, development and growth, and musculoskeletal problem. However, each trial used different parameters and methods to measure various outcomes. RCTs of prenatal interventions in fetus with DS are lacking. The efficacy and safety of specific interventions in DS are still largely unknown. Proper counseling of the potential treatment for pregnant mothers who wish to continue their pregnancy carrying fetus with DS, and to health care professionals who take care of them are not adequate nowadays.

show abstract

Section: Commentmentioning

confidence: 99%

Prenatal and Postnatal Therapies for Down's Syndrome and Associated Developmental Anomalies and Degenerative Deficits: A Systematic Review of Guidelines and Trials

Hasina

Wang²

2022

Front. Med.

View full text Add to dashboard Cite

show abstract

Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review

Sagar,

Walther‐Jallow,

Götherström

et al. 2023

Prenatal Diagnosis

View full text Add to dashboard Cite

ObjectiveTo investigate the maternal and fetal safety of In utero stem cell transplantation (IUSCT).MethodsMedline®, Embase and Cochrane library (1967−2023) search for publications reporting IUSCT in humans. Two reviewers independently screened abstracts and full‐text papers.ResultsSixty six transplantation procedures in 52 fetuses were performed for haemoglobinopathies (n = 14), red cell/bleeding disorders (n = 4), immunodeficiencies (n = 15), storage disorders (n = 7), osteogenesis imperfecta (n = 2) and healthy fetuses (n = 10). The average gestational age was 18.9 weeks; of procedures reporting the injection route, cells were delivered by intraperitoneal (n = 37), intravenous (n = 19), or intracardiac (n = 4) injection or a combination (n = 3); most fetuses received one injection (n = 41). Haematopoietic (n = 40) or mesenchymal (n = 12) stem cells were delivered. The cell dose was inconsistently reported (range 1.8−3.3 × 109 cells total (n = 27); 2.7−5.0 × 109/kg estimated fetal weight (n = 17)). The acute fetal procedural complication rate was 4.5% (3/66); the acute fetal mortality rate was 3.0% (2/66). Neonatal survival was 69.2% (36/52). Immediate maternal and pregnancy outcomes were reported in only 30.8% (16/52) and 44.2% (23/52) of cases respectively. Four fetal/pregnancy outcomes would also classify as ≥ Grade 2 maternal adverse events.ConclusionsShort‐, medium‐, and long‐term maternal and fetal adverse events should be reported in all IUSCT studies.

show abstract

Explores the role of fast fashion in sustainability: stylish killer for the environment

Guru¹,

Grewal²,

Thennarasu³

2022

JTEFT

View full text Add to dashboard Cite

The fashion industry has never been bigger. It turns out more wasteful. With increasing incomes, fashion has also come on its own, evolving from being just clothes in large parts of the world to being a part of ones’ identity. Fashion todays are the second largest biggest polluter in the world after the oil and gas industry. Impacts from the fashion industry include over 92 million tonnes of waste produced per year and 1.5 trillion litres of water consumed. On the basis of these environmental impacts, we outline the need for fundamental changes in the fashion business model, including a deceleration of manufacturing and the introduction of sustainable practices throughout the supply chain, as well a shift in consumer behaviour namely, decreasing clothing purchases and increasing garment lifetimes. These changes stress the need for an urgent transition back to ‘slow’ fashion, minimizing and mitigating the detrimental environmental impacts, so as to improve the long-term sustainability of the fashion supply chain. This article will be help to understanding of the factors affecting the Role of Fast Fashion in Sustainability and Stylish Killer for the Environment.

show abstract

In Utero Haematopoietic Stem Cell Transplantation (Iuhsct)

Cited by 3 publications

References 39 publications

Prenatal and Postnatal Therapies for Down's Syndrome and Associated Developmental Anomalies and Degenerative Deficits: A Systematic Review of Guidelines and Trials

Prenatal and Postnatal Therapies for Down's Syndrome and Associated Developmental Anomalies and Degenerative Deficits: A Systematic Review of Guidelines and Trials

Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review

Explores the role of fast fashion in sustainability: stylish killer for the environment

Contact Info

Product

Resources

About